Skip to Main Content

Paper Details

A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring <i>HRAS</i> Mutations.
Clin Cancer Res
26
2020
Author NameAffiliation
Hye Won LeeDepartment of Hospital Medicine, Yonsei University College of Medicine
Jason K SaKorea University College of Medicine
Byong Chang JeongSamsung Medical Center, Sungkyunkwan University School of Medicine
  • 1 - 3

Datasets

Release 1.2